MRI in Bronchiectasis
Research type
Research Study
Full title
Triple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis
IRAS ID
263504
Contact name
Ian P Hall
Contact email
Sponsor organisation
The University of Nottingham
Eudract number
2019-003052-36
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Cystic Fibrosis (CF) is a genetic disorder affecting more than 10,000 people in the United Kingdom (UK). The biggest cause of ill health and death in CF is lung disease, primarily due to recurrent chest infections and respiratory failure. Non-CF bronchiectasis (bronchiectasis) is a similar lung disease that affects more than 200,000 people in the UK and leads to recurrent chest infections and a significant burden of ill health.
Many new treatments for both CF and bronchiectasis are being developed, but our current methods of assessing lung disease (such as blowing tests and X-ray scans) may not be sensitive enough to monitor their effectiveness in clinical care. As such, there is an urgent need for new state-of-the-art diagnostic tools capable of sensitively evaluating lung disease and guiding treatment decisions.
In this study at the University of Nottingham, we will be using three different types of novel lung magnetic resonance imaging (MRI) scans to help address this need. This study will be conducted over three years and recruit up to 40 people who are either, healthy volunteers, adults with CF, children with CF (aged 12-15 years) or adults with bronchiectasis. Each study participant will be asked to attend a screening visit and between 1 and 3 study visits over a 6-month period. At each study visit, participants will have three different types of lung MRI scan and a special breathing test called Lung Clearance Index (LCI).
The main aims of this study are to tell us if lung MRI scans are reliable in people with CF and bronchiectasis and secondly to determine whether we can use these scans in future research projects that involve cutting-edge treatments for lung disease.
REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
19/NE/0330
Date of REC Opinion
6 Jan 2020
REC opinion
Further Information Favourable Opinion